Clinical trials: Immunoglobulin Treatment
Kawasaki Disease
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
- Trial name
- NCT00760435
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- University of California, San Diego
Upper Respiratory Tract Infections
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
Acute respiratory tract infections (ARTIs), such as acute rhinosinusitis (ARS) and acute otitis media (AOM), are common worldwide and caused by viruses or bacteria entering the body through the mouth and nose.
- Trial name
- NCT05804123
- Testing
- 0.9% NaCl physiological saline Nasal-spraying, LiveSpo Navax®, Augmentin 500Mg Tablet
- Where
- Vietnam
- Volunteers
- 175 people
- Sponsor
- Anabio R&D
Milk Allergy
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.
- Trial name
- NCT00732654
- Testing
- Milk Protein Extract Immunotherapy goal of 4mg/day, Milk Protein Extract Immunotherapy goal of 7mg/day, Milk Powder Immunotherapy goal dose 2000 mg/day
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Graft vs Host Disease
GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease
Acute graft versus host disease (GVHD) remains one of the most significant and potentially lethal complications of allogeneic bone marrow transplantation.
- Trial name
- NCT00228839
- Testing
- Infliximab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Trial name
- NCT00026312
- Testing
- Aldesleukin, Dinutuximab, Isotretinoin
- Where
- 197 sites in United States, Australia and 3 more
- Volunteers
- 1,449 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003870
- Testing
- cyclophosphamide, methotrexate, allogeneic bone marrow transplantation
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Aplastic Anemia
GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT
Objectives 2.1 Primary objectives 1) To observe and compare incidence and severity of aGVHD and cGVHD between the two arms within 2 years after transplantation. 2) To observe and compare the engraftment rate between the two arms.
- Trial name
- NCT05510505
- Testing
- CD20 monoclonal antibody, ATG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acquired Immunodeficiency Syndrome, HIV Infection
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Patients enrolled in NIH protocol 95-I-0133 at the Clinical Center may participate in an extension phase of this study in which the drug prednisone will be eliminated from the treatment regimen.
- Trial name
- NCT00001475
- Testing
- IL-2 plus Anti-TNF or Thalidomide
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma, Allergic
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
This is a multi-centre, randomized, double-blind，placebo parallel-controlled phase III study to evaluate the efficacy and safety of CMAB007 (recombinant humanized anti-immunoglobulin E(IgE) monoclonal antibody for injection) to…
- Trial name
- NCT03468790
- Testing
- CMAB007, Symbicort, Seretide
- Where
- 2 sites in China
- Volunteers
- 393 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Hodgkins Lymphoma, Non-Hodgkin Lymphoma
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
The purpose of this study is to obtain blood (up to 90 ml or 18-teaspoonfuls on one or two occasions) to make LMP1- and LMP2-cytotoxic T-lymphocytes and grow them in the laboratory in such a way that they are able to attack LMP1…
- Trial name
- ALDI (NCT00383097)
- Testing
- LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES, LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Baylor College of Medicine
Cancer
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation.
- Trial name
- NCT00008359
- Testing
- caspofungin acetate, liposomal amphotericin B
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Stage IV
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
This is a retrospective, single-arm real-world study based on the National Anticancer Drug Clinical Application Monitoring Network database.The aim of this study is to evaluate the efficacy and safety of paclitaxel liposome…
- Trial name
- NCT06481553
- Testing
- first line treatment
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Primary Immunodeficiency
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
The purpose of the study is to determine whether biweekly (every 2 weeks) administration of Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%) produces a steady-state area under the…
- Trial name
- NCT04566692
- Testing
- IGSC 20%
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Grifols Therapeutics LLC
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00025181
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
Lower Respiratory Tract Infection, Respiratory Syncytial Virus Infections
Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy
The purpose of this study is to determine the utilization patterns and compliance rates of palivizumab, which is a monoclonal antibody therapy used to prevent respiratory syncytial virus infection.
- Trial name
- NCT00420966
- Where
- 2 sites in Canada
- Volunteers
- 25,003 people
- Sponsor
- Sunnybrook Health Sciences Centre
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
The objective of this study is to develop a rationale for the selective treatment of small fiber neuropathy with immune globulin (IVIG) in the appropriate patients.
- Trial name
- NCT03401073
- Testing
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting
Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)
Primary: Demonstrate the utility of a new electronic data capture (EDC) system (CareExchange™) using infusion nurse measured physical, quality of life (QOL), respiratory, and disability assessments.
- Trial name
- GOOD-SHEPARD (NCT01774331)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- BriovaRx Infusion Services
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
This clinical trial studies fludarabine phosphate and total-body radiation followed by donor peripheral blood stem cell transplant and immunosuppression in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00014235
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center